Does RIS Become Relapsing-Remitting MS or Need Treatment?

If an MRI performed for another reason (such as a headache or minor head injury) reveals spots on the brain or spinal cord that look like multiple sclerosis (MS)—but you have never had any typical MS symptoms—this is called Radiologically Isolated Syndrome (RIS) ^[1]. The short answer to whether RIS becomes relapsing-remitting MS is: it can, but it does not happen to everyone. Research shows that about half of people with RIS develop a first clinical demyelinating event within 10 years ^[2]. Whether RIS needs immediate treatment or simply close observation depends on your unique risk factors and requires an individualized evaluation by an MS specialist ^[3][4].

If You Already Have RRMS

Because this guide focuses on relapsing-remitting MS (RRMS), you might be wondering how RIS applies to you. RIS describes people who have never had a clinical symptom of MS. If you have already been diagnosed with RRMS, any new “silent” spots on your MRI are considered part of your existing MS, not RIS. If you are reading this because you recently discovered older MRIs had spots on them, it is possible you had RIS in the past before your first clinical attack occurred.

What is RIS and How is it Diagnosed?

Finding spots (lesions) on an MRI does not automatically mean you have RIS. Many things can cause white-matter changes, including migraines, normal aging, blood vessel issues, or other inflammatory disorders ^[5][6].

RIS is a diagnosis of exclusion. It means an MS specialist has reviewed your scans, confirmed the lesions are in typical MS locations, taken a detailed medical history to ensure you’ve never had a recognized MS attack, and ruled out other conditions ^[7][3].

The Risk of a First Clinical Event

When RIS progresses, it usually leads to a first clinical demyelinating event (also known as Clinically Isolated Syndrome or CIS), which may or may not immediately meet the full criteria for an RRMS diagnosis ^[8]. Less commonly, it can evolve directly into primary-progressive MS ^[8].

Longitudinal studies tracking specific groups of people with RIS have estimated the cumulative risk of a first clinical event:

• Roughly 34% to 39% experienced an event within 5 years ^[1][9].
• By 10 years, that number rose to about 51% ^[2].

These numbers are population averages from research cohorts, not a prediction for any single individual. Many people with RIS remain symptom-free for years.

Risk Factors for Clinical Activity

Neurologists look for specific clues to estimate a person’s individual risk. Factors associated with a higher likelihood of developing clinical symptoms include:

• Spinal cord or infratentorial lesions: Spots located in the spinal cord or the brainstem/cerebellum (the infratentorial region) ^[2][10].
• Oligoclonal bands: These are specific antibodies found by testing cerebrospinal fluid obtained via a lumbar puncture (spinal tap). They indicate inflammation but are not entirely specific to MS ^[11].
• Gadolinium-enhancing lesions: Spots that light up with contrast dye during an MRI, indicating active, recent inflammation ^[10][2].
• Younger age: Being diagnosed with RIS at a younger age (such as under 37 in some studies) is associated with an earlier clinical event ^[10][12].

While having multiple risk factors increases the statistical likelihood of progression, no single feature guarantees you will develop MS ^[10].

Observation vs. Treatment: Next Steps

Because not everyone with RIS will develop MS, management is highly individualized. An MS specialist will help you weigh the options:

Active MRI and Clinical Surveillance
For many, especially those with lower-risk features, doctors recommend close observation without long-term medication ^[13]. This involves regular clinical exams and follow-up MRIs of the brain (and often the spinal cord) to watch for new lesions ^[4]. The exact schedule is personalized; some experts suggest an initial follow-up within 3 to 6 months, followed by annual imaging, but this varies based on your specific situation ^[14][15]. The appearance of new T2 or gadolinium-enhancing lesions on a follow-up scan independently increases the risk of a future clinical event ^[9].

Disease-Modifying Therapies (DMTs)
For selected people at higher risk, a doctor may discuss starting an MS disease-modifying therapy ^[13][4]. Recent randomized clinical trials (such as the ARISE and TERIS trials) showed that medications like dimethyl fumarate and teriflunomide significantly delayed the occurrence of a first clinical event in people with RIS ^[16][17].

However, taking DMTs for RIS requires careful shared decision-making. These medications carry risks of side effects (such as liver enzyme changes or infection risk), require monitoring, and their use for RIS may be considered off-label depending on where you live ^[3][18][19]. There is also currently a lack of long-term data proving these early treatments prevent permanent disability.

When to Contact Your Doctor
While under observation, you should monitor for meaningful neurologic changes.

• Contact your MS team if you experience new, persistent symptoms that last longer than 24 hours and are not accompanied by a fever or infection—such as new vision loss in one eye, double vision, persistent numbness, or significant weakness.
• Seek emergency medical care if you experience sudden, severe symptoms like sudden one-sided weakness, facial drooping, or speech difficulty, as these could be signs of a stroke or another medical emergency and should not wait for an MS appointment.